1452 results about "Insulin" patented technology

The invention provides isolated Ackermansiella muciniphila, a composition containing the same and an anti-aging and / or anti-oxidation application of the Ackermansiella muciniphila. The Akkermansia muciniphila has the advantages that the average life and the longest life of the Akkermansia muciniphila in a nematode model can be prolonged, the movement activity, the swallowing function and the reproductive capacity of the Akkermansia muciniphila can be improved, the expression of insulin / IGF-1 pathway genes (daf-16, daf-2 and age-1), the expression of antioxidant genes (gst-4 and sod-3) and the expression of longevity related genes (sir-2.1) of the Akkermansia muciniphila can be up-regulated, and the antioxidant capacity and the heat stress tolerance of the Akkermansia muciniphila can be enhanced. It is shown that the Akkermansia muciniphila provided by the invention can be used for preparing or developing the anti-oxidation and anti-aging products, and the anti-oxidation and anti-aging products can be prepared from the Akkermansia muciniphila. The invention provides an efficient and safe solution for anti-aging and / or anti-oxidation.

Techniques disclosed herein relate to nutritional content determination based on gesture detection data. In some embodiments, the techniques involve obtaining gesture detection data corresponding to consumption of a food item or a drink; determining, based on the gesture detection data, nutritional content of the food item or the drink; and causing delivery of insulin in accordance with the nutritional content of the food item or the drink.

The invention provides a tripeptide for promoting bone growth, the tripeptide is VPF, the amino acid sequence of the tripeptide is Val-Pro-Phe, the molecular weight of the tripeptide is 361.44 Da, and the tripeptide belongs to the technical field of functional bioactive peptides. The tripeptide can be prepared from egg yolk protein through enzymolysis separation and purification, can also be obtained through chemical solid-phase synthesis, has a good effect of promoting bone growth, can remarkably improve the growth and proliferation level of osteoblasts in a body, promotes synthesis and secretion of bone matrixes, and has a good application prospect. Meanwhile, the secretion of insulin-like growth factors (IGF-1), transforming growth factors (TGF-beta1) and I-type procollagen amino-terminal peptide (PINP) in the body is efficiently promoted, and good market prospects are achieved.

The invention discloses a glucose response type insulin delivery system as well as a preparation method and application thereof, and belongs to the technical field of biological materials. The glucose response type insulin delivery system provided by the invention comprises a delivery carrier and a bioactive component encapsulated in the carrier, the delivery carrier is a metal polyphenol network formed by carrying out coordination reaction on epigallocatechin gallate and metal ions; the bioactive components comprise glucose oxidase, catalase and insulin. The glucose response type insulin delivery system provided by the invention can adjust the release of insulin according to the concentration of glucose in the surrounding environment, so that the blood glucose is maintained at a normal level.

The invention provides an application of bifidobacterium animalis subsp. Lactis CP-9 in preparation of a product for promoting bone growth and development or improving bone health. Long-term research and a large number of experiments show that the bifidobacterium animalis subsp. Lactis CP-9 can improve the bone volume fraction, the bone trabecula thickness, the bone density and the bone volume of an organism, and can also effectively improve the growth hormone level and the insulin-like growth factor 1 level, so that bone growth and development are promoted. Meanwhile, the bifidobacterium animalis subsp. Lactis CP-9 can effectively improve the N-terminal propeptide level, osteocalcin level, bone morphogenetic protein level and osteoprotectin level of I-type procollagen in a body, and remarkably reduce the amino-terminal peptide level of the I-type collagen and the ligand level of nuclear factor kappa B receptor activating factor, so that osteoblast differentiation is promoted, osteoclast differentiation is inhibited, and osteoclast differentiation is inhibited. Furthermore, bone formation is promoted, bone resorption is inhibited, bone metabolism is improved, and finally the effect of improving bone health is achieved.

The invention provides a tetrapeptide for promoting bone growth, the amino acid sequence of the tetrapeptide is Glu-Pro-Gly-Phe (EPGF), the molecular weight of the tetrapeptide is 448.48 Da, the tetrapeptide can be prepared from egg yolk protein through protease enzymolysis, separation and purification and can also be obtained through chemical solid-phase synthesis, and the tetrapeptide belongs to the technical field of functional bioactive peptides. The tetrapeptide prepared by the invention can promote the growth of osteoblasts in a body and improve the secretion level of insulin-like growth factor-1 (IGF-1), transforming growth factor-beta1 (TGF-beta1) and I-type procollagen amino terminal peptide (PINP) in cells, so that the effect of promoting bone growth is achieved, and a new functional component is provided for a product for improving bone growth.

The invention discloses a blood glucose concentration prediction method combined with a neural network, and relates to the technical field of blood glucose concentration prediction.The method comprises the steps that continuous blood glucose monitoring equipment interacts with a target user to conduct blood glucose monitoring, and a dynamic blood glucose concentration sequence in a preset monitoring window is extracted; acquiring an exercise data set, a food intake data set, an insulin use record set and an environment monitoring data set of the target user in the preset monitoring window; obtaining a blood glucose data topological framework sequence; obtaining a blood glucose feature recognition model; performing cross-scale mapping interaction analysis to obtain blood glucose associated features; training a blood glucose concentration prediction network layer; and performing blood sugar concentration prediction on the blood sugar related characteristics to obtain a blood sugar concentration prediction result. The technical problem that in the prior art, blood glucose concentration prediction is conducted in a single dimension, and the accuracy of the prediction result is low is solved, and the technical effect of improving the accuracy and timeliness of blood glucose concentration prediction is achieved.

The invention relates to the technical field of microorganisms, in particular to a culture medium and a method for culturing Ackermania muciniphila for activating Amuc-1260 by using lambda-carrageenan as a carbon source, according to the culture method, the lambda-carrageenan is used for replacing a traditional carbon source, thallus growth and proliferation can be remarkably promoted, the effect is optimal under the condition of 2.00 g / L, and the culture cost is low. Compared with the conventional carbon source (glucose), the carbon source is improved by 92.91%. Further research finds that the lambda-carrageenan can induce the Akk bacteria to up-regulate the expression of glycoside hydrolase such as Amuc-1260 and enhance the activity of pathways such as glycosaminoglycan degradation, amino acid metabolism and insulin signals, so that the metabolic adaptability and energy utilization efficiency of the bacteria are improved. Meanwhile, the Akk bacteria secrete more functional short-chain fatty acids such as acetic acid, propionic acid and the like under the condition, and have the effects of regulating intestinal health and maintaining metabolic homeostasis. The invention provides a new theoretical basis and technical support for large-scale culture of Akk bacteria and development of a metabiotic product.

The invention discloses a serum-free adipogenic differentiation method for porcine adipose precursor cells, and relates to the technical field of mammalian animal cell differentiation.In the adipogenic differentiation process, an induced differentiation culture medium and a maintained differentiation culture medium are sequentially used, and the induced differentiation culture medium is composed of a basic culture medium and cell culture auxiliary factors; the cell culture auxiliary factor is composed of 66nmol / L insulin, 33 [mu] mol / L biotin, 17 [mu] mol / L pantothenic acid, 0.1 [mu] mol / L dexamethasone, 0.25 mmol / L IBMX, 1 [mu] mol / L rosiglitazone, 150 [mu] mol / L sodium oleate and 10 [mu] g / mL transferrin; the maintenance differential medium removes IBMX and rosiglitazone on the basis of inducing the differential medium. The serum-free adipogenic differentiation method for the porcine fat precursor cells, provided by the invention, is good in differentiation effect and high in repeatability.

The invention belongs to the technical field of biological detection, and particularly relates to a disease marker fluorescence instant detection method based on protein scaffold DNA-Cu2 + functional nanospheres, which comprises the following steps: combining an insulin-like growth factor 1 (IGF-1) aptamer or cortisol aptamer, protein-DNA and DNA-metal ions; the protein scaffold DNA-Cu < 2 + > multifunctional integrated nanospheres are synthesized by a one-step method at room temperature. Based on the function integration of the nanosphere, one-step detection of IGF-1 or cortisol is realized, a plurality of analysis modes including fluorescence detection and smartphone-RGB are provided by combining a test strip and smartphone red, green and blue (RGB) analysis technologies, and a rapid and sensitive disease marker instant detection method is constructed. Finally, rapid and convenient detection of multiple markers in hundreds of clinical samples of multiple diseases is realized, and a new solution is provided for paper-based fluorescence POCT.

A method may include obtaining blood glucose level readings over a diurnal period for each of a plurality of days and determining an estimated variability of the blood glucose levels over the diurnal period for the plurality of days. The method may also include modifying, based on the estimated variability of the blood glucose level, a target blood glucose level to a modified target blood glucose level, and delivering insulin, using an insulin pump, during the diurnal period based on the modified target blood glucose level.

Described herein are methods of treating or reducing the severity of thyroid eye disease (TED), as well as antibodies that bind and inhibit signaling through the insulin-like growth factor receptor 1, useful in the methods.

There is provided the use of Lactobacillus paracasei or a afterbiogen in the preparation of a pharmaceutical composition or a food composition for the production of tryptophan-binding cholic acid. The Lactobacillus paracasei or the afterbiogen thereof can be used to prevent and / or treat metabolic diseases or to promote the production of GLP-1 and / or insulin, or to maintain blood glucose healthy levels, to maintain blood lipid health and / or to control fat in the body.

The invention provides application of combined cholic acid TrpCA and producing bacteria thereof in treating and preventing metabolic diseases. The present invention relates to the use of tryptophan-binding cholic acid or a producing bacterium thereof in the preparation of a composition for preventing and / or treating a metabolic disease or for promoting the production of GLP-1 and / or insulin. The inventor finds for the first time that tryptophan-bound cholic acid can remarkably promote secretion of GLP-1 on an in-vivo animal model and an in-vitro cell model, the effects of reducing weight, reducing blood sugar and relieving the symptoms of the non-alcoholic fatty liver disease are achieved, and the same metabolism improvement effect can also be achieved through planting of probiotics capable of generating cholic acid TrpCA.

In some examples, a system includes a glucose sensor configured to generate a signal indicative of a blood glucose level of a patient, a medical device configured to deliver insulin to the patient, a peritoneal dialysis (PD) device, and control circuitry. The control circuitry is configured to control the PD device to deliver PD therapy to a patient during a PD cycle, determine a blood glucose level of the patient during the PD cycle based on a signal from the glucose sensor, determine that the blood glucose level is greater than or equal to a predetermined blood glucose level threshold, and control the medical device to deliver insulin to the patient in response to determining the blood glucose level is greater than or equal to the predetermined blood glucose level threshold.

The invention discloses a portable wound surface protection brace and an application method thereof, and belongs to the technical field of medical instruments. The brace is of a cylindrical structure, is made of EVA materials, has flexibility, non-toxic characteristics and good supporting performance and is externally wrapped with cotton cloth and provided with ventilation through holes, high-density cotton strips are fixed to the two ends of the inner wall to form a hollow structure, and the circumference of the outer wall can be adjusted through at least three sets of bandages with hook-and-loop fasteners. And an antibacterial coating is added, so that clinical application is expanded. During application, a wound surface is subjected to liquid extraction and hydrogen peroxide cleaning in the earlier stage and then covered with insulin mixed normal saline gauze, and the dressing is prevented from making contact with clothes in cooperation with a brace; and smearing mupirocin ointment in the later stage and performing infrared irradiation, and continuously using the brace to keep the wound dry and zero contact. The brace can be repeatedly used, can adapt to various wound types and patient body types, effectively solves the problems of wound adhesion and friction in traditional nursing, creates a high-oxygen healing environment, remarkably shortens wound healing time, relieves pain of patients and improves life quality, and has good clinical application and popularization value.

Disclosed are techniques to establish a modified pump rate that mitigates the effects of a pump occlusion and enables a recommended dosage of insulin to be output by a pump mechanism over the course of a control cycle. In an example, the pump rate may be reduced by adding a calculated time interval between application of actuation commands to extend the amount of time over which insulin may be output by the pump mechanism.

The invention provides an injection pen special for preventing acupuncture injury of insulin, and relates to the technical field of medical instruments, the injection pen comprises an injection pen body, the outer circumference of the injection pen body is provided with a metering observation window, the rear end face of the injection pen body is provided with an injection push key, and the front end face of the injection pen body is provided with a piston rod. The injection needle is sleeved with the inner needle cap and the outer needle cap, multiple protections are formed, it is ensured that the injection needle is properly protected in the transportation, storage and use processes, the probability of pricking injury is greatly reduced, the rubber column is fixedly installed at the front end of the outer needle cap, for old people with poor eyesight, a needle head can be inserted into the rubber column, and the rubber column is fixedly installed at the front end of the outer needle cap. The needle head can be hidden, and the problems that old people with poor eyesight are difficult to read metering scales, and a replaced injection needle is prone to hurting a user and other people are solved.

Some embodiments of an infusion pump system can be used to determine a user's total insulin load (TIL) that provides an accurate indication of the insulin previously delivered to the user's body which has not yet acted. In particular embodiments, the TIL can account for both the bolus deliveries and the basal deliveries that have occurred over a period of time. Such information may be useful, for example, when the infusion pump is operated in conjunction with a continuous glucose monitoring device.

Disclosed is an acylated insulin, a pharmaceutical formulation thereof, a pharmaceutical composition thereof with a long-acting GLP-1 compound, and a medical use of the acylated insulin, the pharmaceutical formulation and the pharmaceutical composition. Compared with insulin degludec or other insulin derivatives, the acylated insulin has an unexpected, significantly increased drug effect, a longer duration of action, a longer in vivo half-life, an excellent bioavailability, as well as better physical and chemical stabilities.

The invention discloses a culture medium and application thereof, and a method for in-vitro separation culture and adipogenic differentiation of precursor adipocytes in goat muscle, and relates to the technical field of cell culture, the culture medium comprises the following components: 8-12 [mu] g / mL of insulin, 8-12% by volume of fetal calf serum, 95-105 U / mL of penicillin, 95-105 [mu] g / mL of streptomycin and the like. On the basis of the prior art, a proper amount of liquiritin and pilocarpine are mainly added into a culture medium, and synergistic cooperation of the liquiritin and pilocarpine is found, so that the adipogenic differentiation capacity of cells such as mesenchymal stem cells and precursor adipocytes is remarkably improved, and the application range is wide. On the basis, the invention also provides a complete set of perfect in-vitro isolated culture and adipogenic differentiation method of the goat intramuscular precursor adipocytes, and a method and a way are provided for a series of researches developed through the goat primary intramuscular precursor adipocytes in the future.

The invention provides a tissue protection solution and application thereof. The tissue protection liquid comprises a basic culture medium; vitamins, wherein the vitamins comprise vitamin E; the antioxidant is prepared from at least one of N-acetylcysteine amide, superoxide dismutase and catalase; and a specific cell factor, wherein the specific cell factor comprises at least one of a ROCK inhibitor Y27632 and insulin. Therefore, when the tissue protection liquid is used for storing and transporting a tissue sample, the loss in the process from tissue sample separation to experiment starting can be reduced, the function and activity of tissue cells are ensured, and the success rate of establishment of various primary tissue cultures is effectively improved.

The invention discloses a serum-free culture medium for in-vitro proliferation of poultry muscle stem cells and application of the serum-free culture medium, and belongs to the technical field of cell engineering, a basic serum-free culture medium is DMEM-F12, a complete serum culture medium is a mixture of DMEM-F12 added with 10% of fetal calf serum and 1% of mycillin, and the volume ratio of a culture medium supplement to the basic culture medium is 1: 1000; the serum-free culture medium contains a supplement; the supplement comprises the following compositions: insulin, transferrin, fibroblast growth factor 2, epidermal growth factor, catalase, ethanolamine, vitamin B12, linoleic acid, linolenic acid, retinol acetate, tocopherol, L-alanine, L-proline, sodium selenite, sodium pyruvate, reduced glutathione, berberine hydrochloride and analogues thereof.

The invention belongs to the technical field of biological medicines, and particularly discloses an insulin-like growth factor-1-linker polypeptide-collagen, and the linker polypeptide has an amino acid sequence as shown in SEQ ID No.1. The N end of the designed and synthesized linker polypeptide simulates an IGF-1 receptor structure and can be combined with IGF-1, the C end of the linker polypeptide is rich in lysine residues and can be covalently cross-linked to collagen through glutamine transaminase, the attachment time of the IGF-1 in endometrium is prolonged, and endometrium thickening and endometrium injury repair are effectively promoted. The protein solution for promoting endometrial injury repair provided by the invention can form a stable repair microenvironment on the surface of the endometrial, promote the number recovery of endometrial glands with intrauterine adhesion, reduce the fibrosis ratio and promote the thickening of thin endometrial, has the advantages of high histocompatibility, simplicity in preparation, obvious improvement effect and the like, and can be used for preparing a medicine for treating endometrial injury. The method has no potential toxic influence on cells and has a good clinical application prospect.

A method may include generating a first plurality of insulin delivery profiles that include a first series of insulin delivery actions spanning a first time interval, projecting a first plurality of future blood glucose values for each profile of the first plurality of profiles using up-to-date blood glucose levels, selecting one of the first plurality of profiles based upon comparing future blood glucose values for each profile and target blood glucose levels, delivering insulin for a second time interval that corresponds to a first action of the first profile, generating a second plurality of insulin delivery profiles for a third time interval, projecting a second plurality of future blood glucose values for each profile of the second plurality of profiles for the third time interval, and delivering a second dose of insulin for a fourth time interval shorter than the third time interval.

The invention provides an establishment method of umbilical cord mesenchymal stem cells with high expression of IGF-1 (Insulin-like Growth Factor 1) and application of the umbilical cord mesenchymal stem cells in premature ovarian failure. The construction method of the umbilical cord mesenchymal stem cells with high expression of IGF-1 comprises the step of transfecting the umbilical cord mesenchymal stem cells with the IGF-1 gene, so that the umbilical cord mesenchymal stem cells highly express IGF-1. The invention also provides application of the umbilical cord mesenchymal stem cell with high expression of IGF-1 in preparation of drugs for treating premature ovarian failure. According to the invention, the IGF-1 gene is transfected to the hUC-MSC, so that the hUC-MSC highly expresses the IGF-1, and the hUC-MSC secretes a large amount of IGF-1. The ovarian function is improved through the immunoregulation effect of hUC-MS, and meanwhile, the effect of resisting apoptosis of granular cells is achieved through IGF-1 secreted by hUC-MS. And the treatment effect on the premature ovarian failure is achieved through synergism of the two effects.

Embodiments of the present disclosure are directed to miniature insulin patch pump, assistance devices (e.g., for reservoir filling and / or cannula insertion), and methods related thereto. For example, in some embodiments, a substance / drug-delivery patch pump is provided and includes a reusable part (RP) including a power source, a driving mechanism, and an electronic module, and a disposable part (DP), where the disposable part can include at least a plurality of an adhesive base, a reservoir, a dosing mechanism, and a cannula.

The present invention discloses a complete medium for culturing DF-1 cells, including DMEM basal medium 13.7g / L, insulin, non-essential amino acids, transferrin, glutathione, ascorbyl phosphate, sodium selenite, ethanolamine, hydrocortisone, and newborn calf serum. Wherein non-essential amino acids include glycine, alanine, proline, serine, and asparagine. A complete medium for culturing DF-1 cells provided by the present invention can well promote the proliferation of DF-1 cells, can achieve the same proliferation effect as high-concentration fetal bovine serum, and is suitable for the adherent culture of DF-1 cells; using low-concentration newborn calf serum, it is possible to greatly avoid the batch differences, unstable culture results, cytotoxicity, and high risk of carrying pathogens brought by the culture medium with high-concentration serum, narrow application range, expensive fetal bovine serum, and high culture cost; the components are simple, the culture medium preparation process is short in time consumption, the culture efficiency is high, the repeatability is good, and it is suitable for batch production.

The invention provides application of dsRNA in inhibition of reproductive capacity of bemisia tabaci, and belongs to the technical field of pesticides. The dsRNA is one or more of dsBtInR1 and dsBtInR2, and the dsRNA is one or more of dsBtInR1 and dsBtInR2. According to the invention, two bemisia tabaci insulin receptor genes BtInR1 and BtInR2 are found, and after the expression levels of BtInR1 and BtInR2 in bemisia tabaci are knocked down, a JH signal channel can be influenced by interfering an insulin signal channel, and finally, the reproductive capacity of the bemisia tabaci is inhibited, so that a theoretical and application basis is provided for developing and producing green biopesticide for preventing and treating the bemisia tabaci.

A method may include obtaining blood glucose level readings over a diurnal period for each of a plurality of days and determining an estimated variability of the blood glucose levels over the diurnal period for the plurality of days. The method may also include modifying, based on the estimated variability of the blood glucose level, a target blood glucose level to a modified target blood glucose level, and delivering insulin, using an insulin pump, during the diurnal period based on the modified target blood glucose level.